Cumberland Pharmaceuticals (Ticker: CPIX) wants to add a new product in 2011. On the Nashville company's fourth-quarter earnings call Tuesday, CEO A.J. Kazimi said the company is looking for a candidate in the late-stage of development so it can be launched quickly. Cumberland Pharma is looking both externally and internally — at its Cumberland Emerging Technologies subsidiary — for the next addition to its portfolio.
"Our strong financial profile puts us in an ideal position to make such a move in 2011," Kazimi said.
"The test we are developing from discoveries made at St. Jude will yield great improvements in the care of patients with a variety of cancers caused by ALK, including lung cancers, lymphomas, certain sarcomas and other malignancies," said Dr. Josh Nickols, Chief Technology Officer and VP of Research and Development at Insight Genetics. "We believe the test will be able to provide clinicians with the ability to make rapid, informed decisions about therapy selection for their patients during the course of treatment with ALK inhibitors."
“The goal of our organization is to create investment and partnering opportunities, help attract and retain the best talent and provide networking and educational opportunities within the life science industry in Tennessee. Therefore, casting a broader net, both in name and in spirit, and being the organization that advances all the Life Sciences makes sense,” said Life Science Tennessee board member Joe Cook Jr. “Tennessee is already doing amazing work in the life sciences, and the potential to grow this industry in our state and bring with it the economic opportunity, the high-paying jobs, the innovations and the course-altering discoveries is an exciting proposition.”The organization will make it's official debut at its annual meeting on Nov. 12 at the Renaissance Hotel. Click here for information on the event.
“The promise of molecular imaging is to rapidly and noninvasively interrogate tissues of interest without tissue sampling, such as biopsy,” said Manning. “Molecular imaging biomarkers ... may enable us to determine whether a drug is working as early as a few hours after administration as well as predict whether patients will continue to respond over time. This information could spare patients the expense and potential side effects of ineffective therapies.”
POSTDATA: WARRANTY DEEDS